EcoDrugPlus

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSAPEG00000000744
Gene Symbol: HCN4
1 Cross references
210 Possible Orthologues:

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSAPEG00000017641
Gene Symbol: HCRTR2
1 Cross references
201 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSAPEG00000017117
Gene Symbol: IKBKB
1 Cross references
198 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSAPEG00000020416
Gene Symbol: INPP5D
1 Cross references
216 Possible Orthologues:

Insulin Receptor A

Ensembl ID : ENSAPEG00000021882
Gene Symbol: INSRA
1 Cross references
230 Possible Orthologues:

Insulin Receptor B

Ensembl ID : ENSAPEG00000000991
Gene Symbol: INSRB
1 Cross references
201 Possible Orthologues:

Insulin-Like Growth Factor 1a Receptor

Ensembl ID : ENSAPEG00000015850
Gene Symbol: IGF1RA
1 Cross references
206 Possible Orthologues:

Insulin-Like Growth Factor 1b Receptor

Ensembl ID : ENSAPEG00000007516
Gene Symbol: IGF1RB
1 Cross references
204 Possible Orthologues:

Integrin Beta 3a

Ensembl ID : ENSAPEG00000003869
Gene Symbol: ITGB3A
1 Cross references
204 Possible Orthologues:

Integrin Beta 3b

Ensembl ID : ENSAPEG00000016468
Gene Symbol: ITGB3B
1 Cross references
195 Possible Orthologues:

Integrin Subunit Alpha 4

Ensembl ID : ENSAPEG00000002750
Gene Symbol: ITGA4
1 Cross references
226 Possible Orthologues:

Integrin Subunit Alpha 5

Ensembl ID : ENSAPEG00000020475
Gene Symbol: ITGA5
1 Cross references
196 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).